Cervera Carlos, Mestres Carlos A
Servicio de Enfermedades Infecciosas, Hospital Clínic de Barcelona-IDIBAPS, Universitat de Barcelona, Barcelona, España.
Enferm Infecc Microbiol Clin. 2012 Feb;30 Suppl 1:59-63. doi: 10.1016/S0213-005X(12)70074-5.
Daptomycin is a cyclic lipopeptide with a rapid bactericidal effect against Gram-positive bacteria. The pharmacokinetic properties of this drug allow once-daily intravenous infusion as the best posology (including a 2-minute bolus). Because of its ease of administration and excellent safety profile, daptomycin is a first-line agent for use as outpatient antimicrobial parenteral therapy (OPAT). The best evidence supporting this indication exists for the treatment of complicated and uncomplicated skin and soft tissue infections, as well as osteoarticular infections caused by Gram-positive bacteria. For the remaining indications, the use of daptomycin as OPAT should be analyzed in each patient. Information from the EUCORE Registry in Spain indicates that daptomycin has high rates of treatment success in both hospitalized patient and in those included in OPAT programs.
达托霉素是一种环状脂肽，对革兰氏阳性菌具有快速杀菌作用。该药物的药代动力学特性允许每日一次静脉输注作为最佳给药方案（包括2分钟的推注）。由于其给药方便且安全性良好，达托霉素是门诊抗菌药物肠外治疗（OPAT）的一线用药。支持这一适应症的最佳证据存在于治疗复杂和非复杂的皮肤及软组织感染，以及由革兰氏阳性菌引起的骨关节炎感染方面。对于其余适应症，应针对每位患者分析使用达托霉素进行OPAT的情况。来自西班牙EUCORE注册中心的信息表明，达托霉素在住院患者和参与OPAT项目的患者中均具有较高的治疗成功率。
